Aitor González-Titos, Pablo Hernández-Camarero,Shivan Barungi,Juan Antonio Marchal,Julian Kenyon &Macarena Perán
Received 03 Nov 2020, Accepted 23 Apr 2021, Accepted author version posted online: 24 Apr 2021
https://doi.org/10.1080/14712598.2021.1922666
Introduction
Trypsinogen and chymotrypsinogen have been used clinically in tissue repair due to their ability to resolve inflammatory symptoms. Recently, novel evidence has supported the anti-tumourigenic potential of a mixture of trypsinogen and chymotrypsinogen.
